CD274 and non-small cell lung carcinoma: Based on data from the recent phase 3 trial, the PD-1 inhibitor pembrolizumab was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of metastatic NSCLC whose tumors have 50 percent or more PD-L1 expression with no EGFR or ALK genomic tumor aberration11.